blood tests   

Am I at risk of cancer spread?

         C  ancer spreading (metastasis) is associated with > 80% of cancer deaths and may pose a deadly threat to patients even at early cancer stage. A biopsy taken from the original tumor may NOT reflect the most updated condition of cancer in a patient. As a real-time monitoring method, CTC tests give you updated information about whether the cancer cells have spread to the blood. The changes in CTC number indicates the increase/decrease risks of distant metastasis. 

How does OncoSeek CTC test work?

     OncoSeek applies CE-IVD marked and FDA-registered  ClearCell® FX1 microfluidics technology for CTC enrichment. Coupled with OncoSeek 1-Click CTC analyzer software and CellProtect reagent, a succinct and systematic CTC analysis platform was established. The technology has been validated and published (Wong et al. 2017). The test has been applied to >200 patient samples with >95% specificity. One tube of blood (7.5ml) is needed for a test.

TM

TM

High-Quality CTC staining is done with OncoSeek's CellProtect   reagent 

       Reliable CTC counting is done with OncoSeek's 1-Click CTC analyzer software

TM

Low-Quality cell morphology without CellProtect

High-Quality CTC Staining

with

OncoSeek's CellProtect   reagent 

TM

TM

Preserved cell morphology with CellProtect

CTC immunostaining

Reliable CTC Counting 

with

OncoSeek's 1-Click CTC analyzer

CTCs shown in Green

Blood Test Services 

CTC Counting

TM

CTC PD-L1 Exp

TM

CTC Mutation 

Profiler

TM

When to order the tests?

  • Right after Diagnosis

  • During the entire course of the disease

  • Right after Diagnosis

  • During the entire course of the disease

  • Right after Diagnosis

  • During the entire course of the disease

How long to get the results?

3-5 days               •3-5 days                    2-3 weeks

What results could I get?

  • Number of PD-L1(+) CTCs per 7.5 ml of blood 

  • Number of CTCs per 7.5 ml of blood 

  • Presence of clinically relevant mutations on a panel of actionable genes. e.g. EGFR, BRAF, KRAS, NRAS, and more. 

  • A list of targeted drugs matched with the clinically relevant mutations 

Benefits

  • Real-time cancer monitoring 

  • The presence of CTC indicates invasive cancer spreading to the blood from the solid tumor

​​

  • The change of CTC number can indicate change of metastatic risk during the entire course of disease

  • Supports evaluation of drug efficacy in cancer treatment

  • Therapeutic option

PD-L1(+) CTCs may suggest treatment with FDA-approved PD-1/ PD-L1 targeting immunotherapies

  • Therapeutic option 

Clinically relevant and actionable biomarkers may suggest the use of FDA-approved targeting drugs 

References:

1) V. C. Wong et al. Succinct workflows for circulating tumor cells after enrichment: From systematic counting to mutational profiling.      PloS one 12, e0177276 (2017).

 

  • Facebook Social Icon

讓患者的癌症監測更全面

積極抗癌,不要放棄!

願我們一分力量, 送給患者多一份翠綠的希望

電話 31889335 電郵 enquiry@oncoseek-hk.com

地址: 新界香港科學園科技大道西11號生物中心2座1樓119室